

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

PROPOSED CHANGE OF A SUPERVISOR

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

RESIGNATION OF A SUPERVISOR

The board of directors (the “**Board**”) of the Company hereby announces that Mr. Xu Yaming (徐亞明) (“**Mr. Xu**”) has tendered his resignation as a supervisor of the first session of the supervisory board of the Company (the “**Supervisory Board**”) on April 20, 2022 due to re-designation of work with effect from the date on which the annual general meeting of the Company (the “**AGM**”) approved the appointment of a new supervisor. Mr. Xu will continue to perform his duties as a supervisor until the new supervisor takes office.

Mr. Xu has confirmed that he has no disagreement with the Company, the Board and the Supervisory Board, and there are no other matters relating to his resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company (the “**Shareholders**”).

PROPOSED APPOINTMENT OF A SUPERVISOR

In accordance with the articles of association of the Company, the Company Law of the People's Republic of China and applicable laws and regulations, Mr. Wang Feizhou (王飛舟) (“**Mr. Wang**”), as recommended by the Shareholders, is nominated as a candidate of supervisor of the first session of the Supervisory Board. The Supervisory Board has agreed with the abovementioned proposal. The proposal will be submitted to the Shareholders for consideration and approval at the AGM.

The biographical details of Mr. Wang are as follows:

Mr. Wang Feizhou, aged 55, served as a teaching assistant at Jimei Navigation Institute (a predecessor of Navigation School of Jimei University) in Xiamen from August 1987 to March 1993, a lecturer at the School of Information Engineering of Jimei University in Xiamen from March 1993 to August 1998, a visiting scholar sponsored by the Ministry of Education of the PRC at the Centre for Transportation Studies of Nanyang Technological University in Singapore from July 1998 to July 1999, an associate professor at the School of Information Engineering of Jimei University in Xiamen from August 1999 to July 2013, a Telus technical specialist of ATI Group (a Canadian telecom company now merged into AFL Group) from February 2014 to September 2015, the risk control director and chief technical analyst of CAUS HOLDINGS GROUP CO., LTD. in Canada from September 2015 to September 2017, and a fund partner of Shanghai Zhongfu Venture Capital Management Co., Ltd. (上海中孵創業投資管理有限公司) from January 2018 to October 2021. Mr. Wang has been a co-founder and the chairman of the fourth session of the board of supervisors of 1029 CAFÉ SOCIETY, an entrepreneur club in Canada, since April 2015, and a co-founder and the chief technology officer of RAYSENSE TECHNOLOGY CONSULTING INC. in Canada since May 2018. Concurrently, Mr. Wang has been a fund partner of Jiangsu Zhongwei Tengyun Venture Capital Management Co., Ltd. (江蘇中衛騰雲創業投資管理有限公司) since May 2021.

Mr. Wang obtained a bachelor's degree in radio communication engineering from Dalian Maritime University in 1987 and a master's degree in information engineering and control from Dalian Maritime University in 2000.

After being elected at the AGM, Mr. Wang will constitute the first session of the Supervisory Board of the Company together with other members thereof. His term of office shall commence from the date of approval at the AGM until the expiry of the term of the first session of the Supervisory Board. He shall be eligible for re-election upon the expiry of his term of office. The Company will enter into a service contract for supervisor with Mr. Wang upon approval at the AGM. Mr. Wang will not receive remuneration from the Company during his term of office unless otherwise specified in the Company's remuneration scheme for supervisors.

Save as disclosed above, as of the date of this announcement, Mr. Wang confirmed that (1) he did not hold any directorships in any other listed companies in the past three years nor did he have any other major appointments or professional qualifications; (2) he did not hold any positions in the Company or any of its subsidiaries; (3) he did not have any relationship with any directors, supervisors, senior management, substantial Shareholders or controlling Shareholders of the Company or any of its subsidiaries; and (4) he did not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

Save as disclosed above, the Board is not aware of other information on the proposed appointment of Mr. Wang which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the proposed appointment of Mr. Wang that need to be brought to the attention of the Shareholders.

A circular containing, amongst other things, the proposed change of supervisor, together with a notice convening the AGM, will be dispatched to the Shareholders in due course.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. Liu Yong
Chairman

Jiangsu Province, the PRC, April 20, 2022

As at the date of this announcement, the Board comprises Dr. Liu Yong as the chairman of the Board and an executive director, Dr. Chen Jianping and Mr. Li Bu as executive directors, Dr. Hong Kunxue, Dr. Zhou Hongbin, Mr. Zhao Hui, Dr. Du Wei and Dr. Feng Tao as non-executive directors, and Mr. Liang Guodong, Dr. Xia Lijun, Professor Gao Feng and Professor Yuen Ming Fai as independent non-executive directors.